Jan 13, 2022 / 01:30PM GMT
Operator
Good day and welcome to the Salarius Pharmaceuticals Oncology Pipeline Expansion conference call. (Operator Instructions) As a reminder, this call may be recorded. I would now like to turn the call over to [Jason Landa], (inaudible) Strategic Advisors (inaudible).
Unidentified Company Representative Salarius Pharmaceuticals-Company Representative
Good morning and thank you for joining Salarius Pharmaceuticals on today's conference call. Earlier this morning, Salarius Pharmaceuticals issued a press release detailing a cash and stock transaction with DeuteRx LLC for the acquisition of a protein degradation portfolio, which we encourage listeners to read.
The press release can be found in the news section of SalariusPharma.com. Salarius also filed an 8-K this morning, which is available on SalriusPharma.com and SEC.gov.
Before beginning the call, I would like to make the following statement, today, we'll be making certain forward looking statements about operating metrics, future expectations, plans, events and circumstances, including
Salarius Pharmaceuticals Inc Asset Acquisition Agreement with DeuteRx LLC - M&A Call Transcript
Feb 09, 2024
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers